UDK: 616.379-008.64-06-083.31:33

COSTS ASSESSMENT OF DRUG THERAPY OF COMORBIDITIES OF DIABETES MELLITUS TYPE 2 ACCORDING TO THE PHARMACOECONOMICAL STUDY IN THE CITY OF VOLGOGRAD AND VOLZHSKY

D. M. Serdyukova, N. V. Rogova, O. I. Butranova

Волгоградский государственный медицинский университет, кафедра клинической фармакологии и интенсивной терапии

Abstract

According to the pharmacoeconomical analysis «The costs of illness» of ambulatory care of diabetes mellitus type 2 which was hold in outpatient clinics in the city of Volgograd and Volzhsky it was established that there are far more costs of the comorbidities of diabetes mellitus type 2(19554,3 ± 406,5) RUB in comparison with other costs of diabetes. The biggest part of these costs goes to macroangiopathy (80 %). The first place among these costs belongs to arterial hypertension (60,4 %). All in all the drug therapy of comorbidities corresponds to the clinical guidelines and standarts but, however, needs to be corrected. According to the costs the first place in the treatment of arterial hypertension belongs to -adrenoblockers (48,1 %) while ACE-inhibitors, angiotensin II receptor blockers and agonosts to I1-receptors are more recommended by russian and foreign guidelines in this case.

Keywords

pharmaconomy of diabtes mellitus type 2, the costs of the treatment of diabetes mellitus type 2, the cost of illness, comorbidities of diabetes mellitus type 2, drug therapy of diabetes mellitus.

Contacts

Сердюкова Дарья Михайловна — аспирант кафедры клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ и клинической аллергологии ФУВ, ВолгГМУ, e-mail: dariastras@gmail.com